Notable advances in gene therapy include accelerated FDA approvals and clinical trial readiness. Lexeo Therapeutics anticipates a faster biologics license application (BLA) pathway for its Friedreich ataxia cardiomyopathy gene therapy, with discussions of data pooling from ongoing studies. Trogenix raised £70 million in Series A financing to initiate clinical trials on novel glioblastoma gene constructs, and Asimov launched stable producer cell lines to improve adeno-associated virus (AAV) vector manufacturing scalability and quality. Chiesi Group gained exclusive rights to Arbor Biotechnologies’ gene editing therapies targeting rare diseases in a deal potentially worth over $2 billion. These developments highlight momentum in gene editing and therapy commercial translation.